Paramyxovirus vaccine strain for novel coronavirus pneumonia and construction method thereof
US11484588B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2021 |
| Grant date | Nov 1, 2022 |
| Priority date | — |
| Expiry date | Aug 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.